Urogen Pharma Ltd (URGN)

Apr 03, 2025

Long Term Trading Analysis for (URGN) - news.stocktradersdaily.com

Apr 03, 2025

Apr 02, 2025

UroGen Pharma Ltd (URGN) gets rating Resumed from Ladenburg Thalmann - knoxdaily.com

Apr 02, 2025

Mar 31, 2025

Charles Schwab Investment Management Inc. Boosts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Mar 31, 2025

Mar 25, 2025

Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results - Investing.com India

Mar 25, 2025

Mar 25, 2025

Bank of New York Mellon Corp Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Mar 25, 2025

Mar 20, 2025

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 20, 2025

Mar 19, 2025

Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR

Mar 19, 2025

Mar 16, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 16, 2025

Mar 14, 2025

HC Wainwright Expects Reduced Earnings for UroGen Pharma - Defense World

Mar 14, 2025

Mar 13, 2025

(URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Mar 13, 2025

Mar 13, 2025

Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target - MSN

Mar 13, 2025

Mar 12, 2025

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com

Mar 12, 2025

Mar 12, 2025

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright - Defense World

Mar 12, 2025

Mar 12, 2025

UroGen Pharma stock target cut to $55 at H.C. Wainwright By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

UroGen Pharma stock target cut to $36 at Raymond James By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 11, 2025

UroGen Pharma stock target cut to $36 at Raymond James - Investing.com India

Mar 11, 2025

Mar 11, 2025

UroGen Pharma stock target cut to $55 at H.C. Wainwright - Investing.com India

Mar 11, 2025

Mar 11, 2025

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 11, 2025

Mar 11, 2025

UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - Defense World

Mar 11, 2025

Mar 10, 2025

UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks

Mar 10, 2025

Mar 10, 2025

UroGen Pharma Ltd. SEC 10-K Report - TradingView

Mar 10, 2025

Mar 10, 2025

Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 10, 2025

UroGen Pharma shares fall as Q4 results miss estimates By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 10, 2025

UroGen Pharma shares fall as Q4 results miss estimates - Investing.com India

Mar 10, 2025

Mar 10, 2025

Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025

Mar 10, 2025

Urogen Pharma reports wider-than-expected fourth-quarter loss -March 10, 2025 at 10:56 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Mar 10, 2025

Mar 10, 2025

UroGen Pharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Australia

Mar 10, 2025

Mar 10, 2025

UroGen Pharma Posts Wider Loss In Q4Quick Facts - Nasdaq

Mar 10, 2025

Mar 10, 2025

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Joplin Globe

Mar 10, 2025

Mar 09, 2025

Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Mar 09, 2025

Mar 07, 2025

Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com

Mar 07, 2025

Mar 07, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

Mar 07, 2025

Mar 07, 2025

UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 07, 2025

UroGen Strengthens Jelmyto Commercialization: Key Details on New Team RSU Package - Stock Titan

Mar 07, 2025

Mar 06, 2025

UroGen Pharma (URGN) to Release Earnings on Thursday - Defense World

Mar 06, 2025

Mar 04, 2025

BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.

Mar 04, 2025

Mar 02, 2025

How to Take Advantage of moves in (URGN) - Stock Traders Daily

Mar 02, 2025

Feb 27, 2025

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - StockTitan

Feb 27, 2025

Feb 26, 2025

UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright - Defense World

Feb 26, 2025

Feb 25, 2025

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - MSN

Feb 25, 2025

Feb 25, 2025

UroGen stock holds Buy rating, $64 target from H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 25, 2025

Feb 25, 2025

UroGen stock holds Buy rating, $64 target from H.C. Wainwright - Investing.com

Feb 25, 2025

Feb 24, 2025

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - BioSpace

Feb 24, 2025

Feb 24, 2025

Can UroGen's Next Move Transform Urothelial Cancer Treatment? Key Insights Coming at TD Cowen - StockTitan

Feb 24, 2025

Feb 24, 2025

10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey

Feb 24, 2025

Feb 21, 2025

UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance

Feb 21, 2025

Feb 21, 2025

UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World

Feb 21, 2025